Sab Biotherapeutics Stock Performance
| SABSW Stock | USD 0.03 0 11.85% |
SAB Biotherapeutics holds a performance score of 7 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -0.0058, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SAB Biotherapeutics are expected to decrease at a much lower rate. During the bear market, SAB Biotherapeutics is likely to outperform the market. Use SAB Biotherapeutics total risk alpha and the relationship between the downside variance and period momentum indicator , to analyze future returns on SAB Biotherapeutics.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | 10 Best Diabetes Stocks To Buy Under 10 - Insider Monkey | 01/06/2025 |
2 | SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Marketscreener.com | 01/28/2025 |
3 | Acquisition by Moin Andrew of 22115 shares of SAB Biotherapeutics at 1000.0 subject to Rule 16b-3 | 02/27/2025 |
4 | Acquisition by Eddie Sullivan of 1740 shares of SAB Biotherapeutics at 0.88 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 15 M |
SAB |
SAB Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 4.00 in SAB Biotherapeutics on December 18, 2024 and sell it today you would lose (1.47) from holding SAB Biotherapeutics or give up 36.75% of portfolio value over 90 days. SAB Biotherapeutics is currently producing 3.0925% returns and takes up 31.6682% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than SAB, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
SAB Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SAB Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SAB Biotherapeutics, and traders can use it to determine the average amount a SAB Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0977
| Best Portfolio | Best Equity | |||
| Good Returns | SABSW | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 31.67 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.09 actual daily | 61 61% of assets have lower returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average SAB Biotherapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SAB Biotherapeutics by adding it to a well-diversified portfolio.
SAB Biotherapeutics Fundamentals Growth
SAB Stock prices reflect investors' perceptions of the future prospects and financial health of SAB Biotherapeutics, and SAB Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SAB Stock performance.
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Price To Earning | 0.21 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (25.38 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Total Debt | 5.91 M | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Earnings Per Share | 0.29 X | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
About SAB Biotherapeutics Performance
Evaluating SAB Biotherapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SAB Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SAB Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.55) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.58) | (0.55) | |
| Return On Equity | (0.85) | (0.80) |
Things to note about SAB Biotherapeutics performance evaluation
Checking the ongoing alerts about SAB Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SAB Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SAB Biotherapeutics is way too risky over 90 days horizon | |
| SAB Biotherapeutics has some characteristics of a very speculative penny stock | |
| SAB Biotherapeutics appears to be risky and price may revert if volatility continues | |
| SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (25.38 M). | |
| SAB Biotherapeutics generates negative cash flow from operations | |
| SAB Biotherapeutics has a poor financial position based on the latest SEC disclosures |
- Analyzing SAB Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SAB Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining SAB Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SAB Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SAB Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SAB Biotherapeutics' stock. These opinions can provide insight into SAB Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.